NCT03743129 - Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

November 11, 2021

Study Completion Date

November 11, 2021

Conditions

Non-Small Cell Lung Cancer Stage III

Interventions

DRUG

Anlotinib

Anlotinib 12mg p.o, qd

Trial Locations (4)

China-Japan Friendship Hospital, Beijing

Beijing Cancer Hospital, Beijing

Peking University Third Hospital, Beijing

The second hospital of Hebei Medical University, Shijiazhuang